Get started

PHARMA

Best Penny Stocks 🚀 to buy and watch in May 2020NASDAQ:EVFM 😊Please LIKE & FOLLOW for more VIP Hunters signals , penny stocks FDA date of approval - 25th of May Our Strategy with this Stock : This company is a silent player in beer bug vaccination , I'm keeping an eye on it due to the strong upper trend of the company. I'm putting two alarms, one at 2.99 to monitor any anticipatory run up. I'm putting two alarms, one at 2.40 to monitor if it hit the support . What’s the real story : The beauty of Penny stock that I trade in particular , They are ALL pharmaceutical companies. The AMAZING part is 90% of Biotech penny stocks get approved , Still there is 10% that will go the other way ! That's why I'm here for my students to scan all the markets and give them the conclusion that I personally apply . How can you actually use this ? We ONLY trade regarding the news ! Meaning that when we see the anticipatory run UP I start trading it and letting my students and followers take the advantage 👨‍🎓. The Best Part You can follow me and apply my trades for FREE !!! QUESTIONS ? Please comment below , what you have in mind 😊
ELong
by UnknownUnicorn6877177
2
Golden Goose IPO "PPD" This IPO was just listed on FEB, 6th 2020 and will be killing it every earnings and has the potential to big a really big play in the market during these times. The chart I have posted is a 4HR time frame. Definitely one to add to your portfolio for awhile! I can see this being a GOLDEN GOOSE to get into early during these times! options plays are good on this one as well to play. Pivot points and resistance are $26.86 / $28 / $29.37 on the 4HR time frame. The Linear reg. channel is bullish on all time frames up to the 3 min. when it becomes semi neutral. Listed at 100% buy right now on Robinhood NASDAQ:PPD Inc. provides drug development services to the biopharmaceutical industry, focuses on helping customers bring their new medicines to patients around the world. The firm also provides clinical development and laboratory services to pharmaceutical, biotechnology, medical device and government organizations and other industry participants. Its clinical development services include all phases of development (Phase I-IV), peri- and post-approval and site and patient access services; laboratory services offers advanced testing services, including bioanalytical, biomarker, vaccine, good manufacturing practice and central laboratory services. The company was founded by Fred Eshelma in 1985 and is headquartered in Wilmington, NC.
PLong
by The_OnlyRule
Best Penny Stocks 🚀 to buy and watch in May 2020NASDAQ:AQST 😊Please LIKE & FOLLOW for more VIP Hunters signals , penny stocks Our Strategy with this Stock : the company will release the drug for Parkinson disease treatment, The analysts are writing the stock at $17 to drive the sheep to buy the stock , while safe Traders will look for a high price of 6.18 $ . I'm putting two alarms, one at 4.79 to monitor any anticipatory run up. I'm putting two alarms, one at 3.37 to monitor if it hit the support . What’s the real story : The beauty of Penny stock that I trade in particular , They are ALL pharmaceutical companies. The AMAZING part is 90% of Biotech penny stocks get approved , Still there is 10% that will go the other way ! That's why I'm here for my students to scan all the markets and give them the conclusion that I personally apply . How can you actually use this ? We ONLY trade regarding the news ! Meaning that when we see the anticipatory run UP I start trading it and letting my students and followers take the advantage 👨‍🎓. The Best Part You can follow me and apply my trades for FREE !!! QUESTIONS ? Please comment below , what you have in mind 😊
NASDAQ:AQSTLong
by UnknownUnicorn6877177
3
Best Penny Stocks 🚀 to buy and watch in May 2020 NASDAQ:AYTU 😊Please LIKE & FOLLOW for more VIP Hunters signals , penny stocks Our Strategy with this Stock : This company specializes in UV light treatment and the previous history of this company how it strongly reacted with positive news and also negative news . I'm putting two alarms, one at 1.70 to monitor any anticipatory run up. I'm putting two alarms, one at 1.30 to monitor if it hit the support . What’s the real story : The beauty of Penny stock that I trade in particular , They are ALL pharmaceutical companies. The AMAZING part is 90% of Biotech penny stocks get approved , Still there is 10% that will go the other way ! That's why I'm here for my students to scan all the markets and give them the conclusion that I personally apply . How can you actually use this ? We ONLY trade regarding the news ! Meaning that when we see the anticipatory run UP I start trading it and letting my students and followers take the advantage 👨‍🎓. The Best Part You can follow me and apply my trades for FREE !!! QUESTIONS ? Please comment below , what you have in mind 😊
NASDAQ:AYTULong
by UnknownUnicorn6877177
2
OGEN Long into and past earnings! Starting Today!AMEX:OGEN is going to rip into earnings then pull back right before then pop for 100% or more post earnings. Here are my price targets placed for the next week every few days starting with next Monday. DD: OGEN has *1 drug for Oral Mucosis just finished Phase 2 trial, FULL data will be release on earnings call and ironically at the same time they have $15 Million worth of Warrants that will expire the day before. :) Also OGEN as obtained FDA Fast Track approval for this drug and marketing agreements completed in Europe to put it on the shelves immediately if Phase 2 data is good. *1 drug for lowering cholesterol by 70% currently in Phase 1trial, expect results and Ph2 announcement mid/early summer. *$21 Million cash on hand with burn rate of less than 10 Million per year. *This Monday OGEN bought a COVID19 trial drug company with 4,000,000 shares or roughly $1 Million. Trading in a channel, well established bases in this range over the last year or two, no need for extra funding for at least 1 year.
AMEX:OGENLong
by TheStockMarketSniper
1
Ahrvo Daily Movers: Horizon Therapeutics-Bullish on this BiotechAbout Horizon Therapeutics Horizon Therapeutics(ticker: HZNP) is a biopharmaceutical company that focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. It has collaboration agreements with Alliance for Lupus Research, Syneos Health, Inc., and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. HZNP was founded in 2005 and is headquartered in Dublin, Ireland. Ahrvo Stock Rankings Horizon Therapeutics is a top-ten ranked stock on Ahrvo, coming in 6th place (out of over 7,000+ stocks we cover) based on the most recent daily rankings. HZNP has an AhrvoScore (overall score) of 99. Over the last 3 months, Horizon has seen a slight increase in AhrvoScore, up 2 points. Momentum Score, Quality Score, Value Score, and Growth Score are top-notch, clocking in at 94, 80, 99, and 99, respectively. All four sub-scores have increased over the last 3 months. Momentum is up 5 points, Quality up 1 point, Value up 5 points, and Growth up 2 points. Furthermore, Horizon Therapeutics ranks higher than its competitors across all stock scores: Ahrvo Score 99 vs. 35, Momentum Score 94 vs. 62, Value Score 99 vs. 14, Quality Score 80 vs. 18, and Growth Score 99 vs. 42. Ahrvo’s proprietary trading signal also indicates that HZNP is currently a STRONG BUY. Our Take Horizon Therapeutics has performed well relative to the S&P 500 (ticker: SPY) and Nasdaq Biotechnology Index (ticker: IBB). Over the last 6 months, HZNP is up +21%, while the S&P 500 and Biotech Index have returned -8% and +10%, respectively. The company is extremely profitable with net margins of 44%. Last year they earned $573 million on $1.3 billion in revenue. Horizon Therapeutics reports Q1 earnings on Wednesday and is expected to beat analyst expectations. HZNP’s orphan drug portfolio should remain resilient and continue to perform well in the face of economic uncertainty. Orphan drugs are created for extremely rare diseases and drug recipients will need HZNP’s remedies irregardless of what happens with the broader economy. The analyst community is positive on the stock as well. Out of the 12 analysts that cover the company, 10 have HZNP rated as a strong buy (3) or buy (7), with 2 holds. Horizon Therapeutics 12-month median price target is $44.60, representing 25% upside from current levels. -Appo Agbamu, CFA This material is for informational purposes only. Under no circumstances should any information or materials presented be used or construed as an offer to sell, or a solicitation of an offer to buy, any securities, financial instruments, investments, or other services. Any investment made is at your sole discretion. There are many factors that you must consider when making an investment decision, including, but not limited to, product features, risks, whether or not an investment meets your investment objectives, risk tolerance, and other personalized factors. Investing in securities involves risks, and there is always the potential of losing your entire investment.
HLong
by AhrvoStockApp
$TEVA - Weekly Chart 2020Teva's earnings May 7th - www.sec.gov Weekly chart is flashing buy signals with the 50SMA Crossing back under the price. Unknowns: COVID-19 impact on TEVA earnings Decision - Wait until after earnings to get in, still to many unknowns. The reason I like TEVA : Possible Turn-around play, looking for teva to turn net-loss to net-profit in the coming years if they continue to lower debt and start turning profit. Earnings (loss) per share attributable to ordinary shareholders: Basic ($) 2020 - Lower? 2019 - (0.91) even lower? 2018 - (2.35) Lower loss 2017 - (16.26) Huge loss 2016 - 0.07 Smaller profit 2015 - 1.84 Profit Diluted ($) 2019 - (0.91) 2018 - (2.35) 2017 - (16.26) 2016 - 0.07 2015 -1.82 www.sec.gov
NYSE:TEVALong
by AaronX
Easy Swing?GILD is moving with the news these days but the risk vs. reward is looking good, even after coming of the Double Top. I would love to see it bounce of the trend line and buy around $71 for a easy swing to an $80 target. Any good news can make this happen sooner than later. Regardless of the outcome of the trials, big pharma is one of the safest spots to invest right now in my opinion. Take this all with a grain of salt and do your own homework. I honestly have no idea what I'm talking about but just throwing up some ideas to look back at later.
NASDAQ:GILDLong
by lroman90